HYPERPROLACTINEMIA IN PRIMARY INFERTILITY AND OPTIMIZATION OF ITS TREATMENT

Babakulyyeva Ayna; Yuldashev Otabek

Authors

Babakulyyeva Ayna 1st year master’s student in endocrinology ,Urgench state medical institute, Urgench, Uzbekistan
Yuldashev Otabek Phd, associate professor of the department of PID and endocrinology of Urgench state medical institute, Urgench, Uzbekistan

Keywords:

hyperprolactinemia, primary infertility, prolactin, dopamine agonists, ovulatory dysfunction

Abstract

Hyperprolactinemia is one of the most significant endocrine causes of primary infertility in women. Elevated prolactin levels disrupt the hypothalamic–pituitary–ovarian axis, leading to ovulatory dysfunction, menstrual irregularities, and infertility. Early diagnosis and optimized treatment strategies are essential for restoring reproductive function. This study was conducted at the Khorezm branch of the Republican Specialized Scientific and Practical Medical Center of Endocrinology and aimed to evaluate the clinical and hormonal characteristics of women with primary infertility associated with hyperprolactinemia, as well as to optimize therapeutic approaches. The results demonstrate that individualized dopamine agonist therapy significantly improves hormonal balance, ovulatory function, and fertility outcomes.

Downloads

Download data is not yet available.

References

1. Mascarenhas M.N., et al. National, regional, and global trends in infertility prevalence. PLoS Medicine. 2012;9(12):e1001356.

2. Biller B.M.K., et al. Guidelines for the diagnosis and treatment of hyperprolactinemia. Journal of Clinical Endocrinology & Metabolism. 2011;96(2):273–288.

3. Melmed S. Pathogenesis and diagnosis of hyperprolactinemia. The Journal of Clinical Endocrinology & Metabolism. 2011;96(2):273–288.

4. Schlechte J.A. Prolactinoma. New England Journal of Medicine. 2003;349:2035–2041.

5. Colao A., et al. Pregnancy outcomes following cabergoline treatment. Clinical Endocrinology. 2008;68(1):66–71.